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The colon is a site where both local and systemic delivery of drugs can take 
place. Local delivery could, for example, allow topical treatment of 
inflammatory bowel disease. Treatment could be made more effective if it 
were possible for drugs to be targeted directly on the colon. Systemic side 
effects could also be reduced. Colon specific systems might also allow oral 
administration of peptide and protein drugs, which are normally inactivated 
in the upper parts of the gastrointestinal tract. Primary approaches for CDDS 
(Colon Specific Drug Delivery), which includes prodrugs, pH and time 
dependent systems and microbially triggered drug delivery system achieved 
limited success and having limitations. Newly developed CDDS, which 
includes pressure controlled colonic delivery capsules (PCDCS), CODESTM 
and osmotic controlled drug delivery are unique in terms of achieving in vivo 
site specificity and feasibility of manufacturing process. This review also 
focuses on evaluations of CDDS in general. 
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Introduction  
Targeted drug delivery to the colon is highly desirable 
for local treatment of a variety of bowel diseases such 
as (ulcerative colitis, crohan’s disease) amebiosis, 
colonic cancer, and for local treatment of local colonic 
pathologies, and the systemic delivery of protein and 
peptide drugs [1]. 
The colon specific drug delivery system (CDDS) 
should be capable of protecting the drug en route to 
colon (i.e. drug release and absorption should not occur 
in the stomach and the small intestine and bioactive 
agent should not be degraded) [2] and to allow drug 
release only in the colon. The colon is believed to be a 
suitable   site   for  absorption  of  peptides  and  protein  
 
drugs for following reasons: (i) Less diversity and 
intensity of digestive enzymes. (ii) Comparatively 
proteolytic activity of colon mucosa is much less than 
that observed in the small intestine, thus CDDS 
protects peptide drugs from hydrolysis and enzymatic 
degradation in the duodenum and jejunum and 
eventually releases drugs in the ileum or colon which 
leads to greater systemic bioavailability. (iii) The colon 
has along residence time (upto 5 days) [3] and is highly 
responsive to absorption enhancers [4]. 
Oral route is most convenient and preferred route [5] 
but other routes for CDDS may also be used. Rectal 
administration offers the shortest route to targeting 
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drugs on the colon. However reaching the proximal 
part of the colon via rectal administration is difficult. 
Rectal administration can also be uncomfortable for the 
patient and compliance may be less than optimal [6]. 
Drug preparation for intrarectal administration is 
supplied as solutions, foam and suppositories. The 
intrarectal route is used both as a means of systemic 
dosing and for the delivery topically active drug to the 
large intestine [7]. Corticosteroids such as 
hydrocortisone and prednisolone are administered via 
the rectum for the treatment of ulcerative colitis. 
Although these drugs are absorbed from the large 
bowel it is generally believed that their efficacy is due 
mainly to topical application. The concentration of 
drug reaching the colon will depend on formulation 
factors the extent of retrograde spreading and the 
retention time. Foam and suppositories have been 
shown to retained mainly in the rectum and sigmoid 
colon enema solutions have a great spreading capacity. 
Because of the high water absorption capacity of colon, 
the colonic contents are considerably viscous and their 
mixing is not efficient, thus availability of most drugs 
to the absorptive membrane is low. The human colon 
has over 400 distinct species of bacteria as resident 
flora, a possible population of up to 1010 bacteria per 
gram of colonic contents. Among the reactions carried 
out by these gut flora are azoreduction and enzymatic 
cleavage i.e. glycosides. These metabolic processes 
may be responsible for the metabolism of many drugs 
and may also be applied to colon-targeted delivery of 
peptide based macromolecules like insulin by oral 
administration. (Chein) Colonic diseases, drugs and 
target sides are given in table 1. 
 
Advantages of CDDS     
Chronic Colitis e.g. ulcerative colitis and crohan’s 
disease is currently treated with glucocorticoids and 
another anti-inflammatory agent. Administration of 
glucocorticoids e.g. Dexamethasone and methyl 
prednisolone by the oral and i.v. routes produces 
systemic side effects including adenosuppression, 
immunosuppression, Cushinoid symptoms and bone 
resorption. Thus the selective delivery of drug to colon 
could lower the required dose and hence reduce the 
systemic side effects [8]. The system has the advantage 
of more effective therapy a reduced dose and reduced 
undesirable side effects often associated with high 
doses [9].  
Table 1. Colon targeting Diseases, Drugs and Sites 
 
 
Criteria for selection of drug for CDDS   
Drug Candidate 
Drugs which show poor absorption from the stomach 
or intestine including peptide are most suitable for 
CDDS. The drugs used in the treatment of IBD, 
ulcerative colitis, diarrhea and colon cancer are ideal 
candidates for local colon delivery [10]. Criteria for 
selection drugs for CDDS are summarized in table 2.  
 
Drug Carrier 
The selection of carrier for particular drug candidate 
depends on the physiochemical nature of the drug as 
well as the disease for which the system is to be used. 
The factors such as chemical nature, stability and 
partition   coefficient  of  the  drug   and   the   type   of  
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absorption enhancer chosen influence the carrier 
selection. Moreover, the choice of drug carrier depends 
on the functional groups of the drug molecule [11]. For 
example, aniline or nitro groups on a drug may be used 
to link it to another benzene group through an azo 
bond. The carriers, which contain additives like 
polymers (may be used as matrices and hydro gels or 
coating agents) may influence the release properties 
and efficacy of the systems [12]. 
 
Approaches used for site specific drug delivery to 
Colon (CDDS) 
Approaches used for site-specific drug delivery are:  
[A]- Primary approaches for CDDS [10] 
   a - pH sensitive polymer coated drug delivery to 
colon 
    b - Delayed (Time controlled release system) release 
drug delivery to colon 
    c - Microbially triggered drug delivery to colon 


























        
(ii) Azo-polymeric approach for drug delivery 
to colon 
(iii)Polysaccharide based approach for drug 
delivery to colon 
[B]- Newly developed approaches for CDDS [8] 
a. Pressure controlled drug delivery system 
(PCDCS) 
b. CODES™ (A Novel colon targeted delivery 
system)  
c. Osmotic controlled drug delivery to colon 
(OROS-CT) 
 
[A] Primary Approaches for CDDS 
a) pH sensitive polymer coated drug delivery to colon 
In the stomach pH ranges between 1 and 2 during 
fasting but increases after eating [13]. The pH is about 
6.5 in the proximal small intestine and about 7.5 in the 
distal small intestine [11].  From the ileum to the colon 
pH declines significantly. It is about 6.4 in the ceacum. 
However, pH values as low as 5.7 have been measured 
Criteria Pharmacological class Non-peptide drugs Peptide drugs 
Drugs used for local 
effects in colon against 
GIT diseases 
 
Drugs poorly absorbed 
from upper GIT 
 
Drugs for colon cancer 
 
Drugs that degrade in 
stomach and small 
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in the ascending colon in healthy volunteers [9] The pH 
in the transverse colon is 6.6, in the descending colon 
7.0. Use of pH-dependent polymers is based on these 
differences in pH levels. The polymers described as 
pH-dependent in colon specific drug delivery are 
insoluble at low pH levels but become increasingly 
soluble as pH rises. Although a pH-dependent polymer 
can protect a formulation in the stomach and proximal 
small intestine, it may start to dissolve even in the 
lower small intestine, and the site-specificity of 
formulations can be poor [12]. The decline in pH from 
the end of the small intestine to the colon can also 
result in problems Lengthy lag times at the ileo-cecal 
junction or rapid transit through the ascending colon 
can also result in poor site-specificity of enteric-coated 
single-unit formulations [11]. 
 
b) Delayed (Time controlled release system) release 
drug delivery to colon  
Time controlled release system (TCRS) such as 
sustained or delayed release dosage forms are also very 
promising. However due to potentially large variation 
of gastric emptying time of dosage forms in humans 
[13], in this approach colon arrival time of dosage 
forms can not accurately predicted, resulting in poor 
colonical availability. The dosage forms may also 
applicable as colon targeting dosage forms by 
prolonging the lag time of about 5.5 hours (range 5 to 6 
hours), [14]. Disadvantages of this system are- (i) 
Gastric emptying time varies markedly between 
subjects or in a manner dependent on type and amount 
of food intake.(ii) Gastrointestinal movement, 
especially peristalsis or contraction in the stomach 
would result in change in gastrointestinal transit of the 
drug  [10]. (iii) Accelerated transit through different 
regions of the colon has been observed in patients with 
the IBD, [15], the carcinoid syndrome and diarrhea and 
the ulcerative colitis [16]. Therefore time dependent 
systems are not ideal to deliver drugs to colon 
specifically for the treatment of colon related diseases. 
Appropriate integration of pH sensitive and time 
release functions into a single dosage form may 
improve the site specificity of drug delivery to the 
colon. That is since the transit time of dosage forms in 
the small intestine is less variable i.e. about 3±1 hour 
[14]. The time-release function (or timer function) 
should work more efficiently in the small intestine as 
compared the stomach. In the small intestine drug 
carrier will be delivered to the target side and drug 
release will begin at a predetermined time point after 
gastric emptying. On the other hand in the stomach, the 
drug release should be suppressed by a pH sensing 
function (acid resistance) in the dosage form, which 
would reduce variation in gastric residence time [10]. 
 
Enteric-coated time-release press coated (ETP) tablets 
ETP tablets are composed of three components, a drug 
containing core tablet (rapid release function), the press 
coated swellable hydrophobic polymer layer (Hydroxy 
propyl cellulose layer, time release function) and an 
enteric coating layer (acid resistance function), [17]. 
Tablet does not release the drug in the stomach due to 
the acid resistance of the outer enteric coating layer. 
After gastric emptying, the enteric coating layer rapidly 
dissolves and the intestinal fluid begins slowly erode 
the press coated polymer (HPC) layer and when the 
erosion front reaches the core tablet, rapid drug release 
occurs since the erosion process takes a long time there 
is no drug release period (lag phase) after gastric 
emptying. The duration of lag phase controlled either 
by the weight or composition of the polymer (HPC) 
layer [18] Figure 1.  
 
Figure 1. Design of Enteric coated-timed release 
press coated tablets (ETP tablets). 
 
c) Microbially triggered drug delivery to colon 
The microflora of colon is in the range of 1011 -1012 
CFU/mL [15], consisting mainly of anaerobic bacteria, 
e.g. Bacteroides, Bifidobacteria, Eubacteria, Clostridia, 
Enterococci, Enterobacteria and Ruminococcus etc. 
This vast microflora fulfills its energy needs by 
fermenting various types of substrates that have been 
left undigested in the small intestine, e.g. di- and tri-
saccharides, polysaccharides etc [17]. For this 
fermentation the microflora produces a vast number of 
enzymes like glucoronidase, xylosidase, arabinosidase, 
galactosidase, nitroreductase, azareducatase, 
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deaminase, and urea dehydroxylase [13]. Because of 
the presence of the biodegradable enzymes only in the 
colon, the use of biodegradable polymers for colon-
specific drug delivery seems to be a more site-specific 
approach as compared to other approaches [12]. These 
polymers shield the drug from the environments of 
stomach and small intestine and are able to deliver the 
drug to the colon. On reaching the colon, they undergo 
assimilation by micro-organism or degradation by 
enzyme or break down of the polymer back bone 
leading to  a  subsequent  reduction  in  their  molecular 
weight and thereby loss of mechanical strength. They 
are then unable to hold the drug entity any longer [18]. 
 
 
Table 3. Prodrugs evaluated for colon specific drug delivery 
 
 
(i) Prodrug approach for drug delivery to colon 
Prodrug is pharmacologically inactive derivative of a 
parent drug molecule that requires spontaneous or 
enzymatic transformation in-vivo to release the active 
drug. For colonic delivery the prodrug are designed to 
undergo minimal absorption and hydrolysis in the 
tracts of upper GIT and undergo enzymatic hydrolysis 
in the colon, there by releasing the active drug moiety 
from the drug carrier. Metabolism of azo compounds 
by intestinal bacteria is one of the most extensively 
studied bacterial metabolic processes [19]. A number 
of other linkages susceptible to bacterial hydrolysis 
especially in the colon have been prepared where the 
drug is attached to hydrophobic moieties like amino 
acids, glucoronic acids, glucose, galactose, cellulose 
etc. Limitations of prodrug approach is that it is not 
Carrier Drug investigated  Linkage 
hydrolysed 
In vitro / in 
vivo model 
used 
Performance of the 
Prodrug / conjugates 
Reference 











Site specific with a lot of 
side effects associated with 
SP 
Delivers 2 molecules of 5-
ASA as compared     to 
sulphasalazine  
Khan et al, 
1977 
 
Chan et al, 
1983 
Amino acid conjugates 
glycine 
Salicylic acid Amide 
linkage 
Rabbit  Absorbed from upper GIT, 
though metabolized by 




Tyrosine/methionine  Salicylic acid  Amide 
linkage  
Rabbit  Absorbed from upper GIT, 
though metabolized by 




L – Alanin/D-Alanine  Salicylic acid  Amid 
linkage 
In vitro  Salicylic acid-l-alanine was 





hydrolysis thereby showing 
enantiospecific hydrolysis  
Nakamura et 
al., 1992b 
Glycine  5-ASA Amid linkage In vitro  Prodrug was stable in 
upper GIT and was 
hydrolysed by cecal 
content to release 5-ASA 
Jung et al., 
1998 




Rat  Dexamethasone prodrug 
was site specific and 60% 
of oral dose reached the 
cecum. Only 15% of 
prednisolone prodrug 
reached the cecum. 
Friend et al, 
1984  
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very versatile approach as it’s formulation depends 
upon the functional group available on the drug moiety 
for chemical linkage. Further more prodrugs are new 
chemical entities and need a lot of evaluation before 
being used as carriers [20]. A number of prodrugs have 
been outlined in table 3. 
 
(ii) Azo-polymeric prodrugs 
Newer approaches are aimed at use of polymers as 
drug carriers for drug delivery to the colon. Both 
synthetic as well as naturally occurring polymers are 
used for this purpose. Subsynthetic polymers have been 
used to form polymeric prodrug with azo linkage 
between the polymer and drug moiety [21]. These have 
been evaluated for CDDS, various azo polymers have 
also been evaluated as coating materials over drug 
cores. These have been found to be similarly 
susceptible to cleavage by the azoreducatase in the 
large bowel. Coating of peptide capsules with polymers 
cross linked with azoaromatic group has been found to 
protect drug from digestion in the stomach and small 
intestine. In the colon the azo bonds are reduced and 
the drug is released [22]. A number of azo-polymeric 
prodrugs have been outlined in table 4. 
 
 
Table 4. Some Azo polymer-based drug delivery systems evaluated for colon-specific drug delivery with 
summary of results obtained. 
 
(iii) Polysaccharide based delivery systems 
 Use of naturally occurring polysaccharides is 
attracting lot of attention for drug targeting to the colon 
since these polymers of monosaccharides are found in 
abundance, have wide availability are inexpensive and 
are available in a verity of a structures with varied 
properties [23]. They can be easily modified 
chemically and biochemically and are highly stable, 
safe, nontoxic, hydrophilic and gel forming and in 
addition biodegradable. These include naturally 
occurring polysaccharides obtained from plant (guar 
gum, inulin) animal (chitosan, chondrotin sulphate) 







Summary of the results 
obtained 
Reference  







Rats dogs  These capsules showed 
biological response 
characteristics of these 
peptide hormones in dog 
though it varied 
quantitatively. 
Saffron et al., 
1986, 1988, 1991 






Hydrogen  5-fluorouracil In vitro  Drug release was faster 
and greater in human 
fecal media compared to 
simulated gastric and 
intestinal fluids 






Budesonide  Rat  These azopolymer-
coated pellets were 
useful for colon-specific 
delivery of budesonide 
to bring healing in 
induced colitis. 
Tozaki et al., 
1999 










These films were 
degraded by 
azoreductase. The 
permeability of 5-ASA 
from lactobacillus 
treated films was 
significantly higher than 
that of control  
Chavan et al., 
2001 
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algal (alginates) or microbial (dextran) origin. These 
are broken down by the colonic microflora to simple 
saccharides  [24].  So  these  fall  into the  category  of  
“generally regarded as safe” (GRAS). A number of 
polysaccharides based delivery systems have been 
outlined in table 5.  
 
                                 Table 5. Polysaccharides investigated for colon specific drug delivery 
 
 
[B] Newly developed approaches for CDDS 
a) Pressure-controlled drug-delivery systems 
As a result of peristalsis, higher pressures are 
encountered in the colon than in the small intestine. 
Takaya et al. (1995) have developed pressure 
controlled colon-delivery capsules prepared using an 
ethylcellulose, which is insoluble in water. In such 
systems drug release occurs following disintegration of 
a water-insoluble polymer capsule as a result of 







In vitro/ in 
vivo model 
used 
Performance of the system 
References 
 





In vitro Little release of CF in upper GIT conditions 
and 100% drug release in 33% cecal contents 
within 4 h of dissolution.  
Tozaki et al., 
1997 
 Insulin  Enteric-coated 
chitosan 
capsules 
Rat Chitosan capsules carried the drug to the 
colon. Improvement in insulin absorption 
seen by co-administration of absorption 
enhancers  





Chitosan phthalate.  
Sodium 
diclofenace 
As matrices In vitro  Reduced drug release was seen in acidic 
conditions and improved dissolutions under 
basic conditions 
Aiedeh et al, 
1999 
Pectin (used as 
calcium salt) 
Indomethacin Matrices In vitro In the presence of rat cecal content drug 
release was 60.8±15.7% as compared to 














In the in vivo studies neither of the two types 
of the tablets could resist an initial leak of the 
insulin from the tablet and it was suggested 
tat and additional protection was required for 








Amidated pectin / 
calcium pectinate 
Ropivacaine  matrix tablet 
with ethyl 
cellulose as drug 
matrix additive 
In vitro Amidated pectin was more susceptible to 
pectinolytic enzymes as compare to calcium 
pectinate. Addition of ethyl cellulose 
increased the tablets strength and dissolution 
rate coating this formulation with Eudragit 
L100 reduced drug release in upper GIT 
conditions without effecting enzyme 
degradability.      
































Drug release increases in presence of rat 
cecal content. Also it was observed that as 
cross linking increased, drug release 
decreased  
 
In basic media enteric coating dissolves and 
beads swell to exceed the strength of 
aquacoat film, which then burst releasing the 
drug. 





Shun et al, 
1992 
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ethylcellulose membrane is the most important factor 
for disintegration of the formulation [25]. The system 
also appeared to depend on capsule size and density. 
Because of reabsorption of water from the colon, the 
viscosity of luminal content is higher in the colon than 
in the small intestine. It has therefore been concluded 
that drug dissolution in the colon could present a 
problem in relation to colon-specific oral drug delivery 
systems. In pressure-controlled ethylcellulose single-
unit capsules the drug is in a liquid. Lag times of three 
to five hours in relation to drug absorption were noted 
when pressure-controlled capsules were administered 
to human [26]. 
 
b) Novel colon targeted delivery system (CODESTM) 
CODESTM is a unique CDDS technology that was 
designed to avoid the inherent problems associated 
with pH-or time –dependent systems. CODESTM is 
combined approach of pH dependent and microbially 
triggered CDDS. It has been developed by utilizing a 
unique mechanism involving lactulose, which acts as a 
trigger form site specific drug release in the colon. 
(Figure. 2) the system consists of a traditional tablet 
core containing lactulose, which is over coated with, 
and acid soluble material, Eudragit E, and then 
subsequently over coated with an enteric material, 
Eudragit L. The premise of the technology is that the 
enteric coating protects the tablet while it is located in 
the stomach and then dissolves quickly following 
gastric emptying. The acid soluble material coating 
then protects the preparation as it passage through the 
alkaline pH of the small intestine. Once the tablet 
arrives in the colon the bacteria will enzymatically 
degrade the polysaccharide (lactulose) into organic 
acid. This lowers the pH surrounding the system 
sufficient to affect the dissolution of the acid soluble 
coating and subsequent drug release (Figure 2) [27]. 
 
(c) Osmotic controlled drug delivery (ORDS-CT) 
The OROS-CT (Alza corporation) can be used to target 
the drug locally to the colon for the treatment of 
disease or to achieve systemic absorption that is 
otherwise unattainable [19]. The OROS-CT system can 
be single osmotic unit or may incorporate as many as 
5-6 push-pull units, each 4mm in diameter, 
encapsulated with in a hard gelatin capsule (Figure 3). 
Each bilayer push pull unit contains an osmotic push 
layer and a drug layer, both surrounded by a semi 
permeable membrane. An orifice is drilled through the 
membrane next to the drug layer. Immediately after the 
OROS-CT is swallowed, the gelatin capsule containing 
the push-pull units dissolves. Because of its drug-
impermeable enteric coating, each push-pull unit is 
prevented from absorbing water in the acidic aqueous 
environment of the stomach and hence no drug is 
delivered. As the unit enter the small intestine, the 
coating dissolve in this higher pH environment (pH 
>7), water enters the unit, causing the osmotic push 
compartment to swell and concomitantly creates a 
flowable gel in the drug compartment. Swelling of the 
osmotic push compartment forces drug gel out of the 
orifice at a rate precisely controlled by the rate of water 
transport through the semipermeable membrane. For 
treating ulcerative colitis, each push pull unit is 
designed with a 3-4 hour post gastric delay to prevent 
drug delivery in the small intestine. Drug release 
begins when the unit reaches the colon. OROS-CT 
units can maintain a constant release rate for up to 24 h 
in the colon. Evaluation of colon specific dissolution 
system. Various in vitro / in vivo evaluation techniques 
has been developed and proposed to test the 




Figure 2. Schematics of conceptual design of 
CODESTM. 
 
In vitro evaluation   
No standardized evaluation technique is available for 
evaluation of CDDS because an ideal in vitro model 
should posses the in vivo conditions of GIT such as pH, 
volume, stirring, bacteria, enzymes, enzyme activity 
and other components of food. Generally these 
conditions are influenced by the diet and physical stress 
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and these factors make it difficult to design a slandered 
in vitro model. In vitro model used for CDDS are:  
a) In vitro dissolution test  
Dissolution of controlled-release formulations used for 
colon-specific drug delivery are usually complex, and 
the dissolution methods described in the USP cannot 
wholly mimic in vivo conditions such as those relating 
to pH, bacterial environment and mixing forces [29].  
Dissolution tests relating to CDDS may be carried out 
using the conventional basket method. Parallel 
dissolution studies in different buffers may be 
undertaken to characterize the behavior of formulations 
at different pH levels. Dissolution tests of a colon-
specific formulation in various media simulating pH 
conditions and times likely to be encountered at various 
locations in the gastrointestinal tract [25]. The media 
chosen were, for example, pH 1.2 to simulate gastric 
fluid, pH 6.8 to simulate the jejunal region of the small 
intestine, and pH 7.2 to simulate the ileal segment.  
Enteric-coated capsules for CDDS have been 
investigated in a gradient dissolution study in three 
buffers. The capsules were tested for two hours at pH 
1.2, then one hour at pH 6.8, and finally at pH 7.4 [26]. 
b) In vitro enzymatic test 
For this there are 2 tests: 
i) Incubate carrier drug system in fermenter containing 
suitable medium for bacteria (Streptococcus faccium or 
B.ovatus) amount of drug released at different time 
intervals determined. 
 ii)  Drug release study is done in buffer medium 
containing enzymes (enzyme pectinase, dextranase), or 
rat or guinea pig or rabbit cecal contents. The amount 
of drug released in particular time is determined, which 
is directly proportional to the rate of degradation of 
polymer carrier [28].   
 
In vivo evaluation 
A number of animals such as dogs, guinea pigs, rats 
and pigs are used to evaluate the delivery of drug to 
colon because they resemble the anatomic and 
physiological conditions as well as the microflora of 
human GIT. While choosing a model for testing a 
CDDS, relative model for the colonic diseases should 
also be considered. Eg. Guinea pigs are commonly 
used for experimental IBD model. The distribution of 
azoreductase and glucouronidase activity in the GIT of 
rat and rabbit is fairly comparable to that in the human. 
For rapid evaluation of CDDS a novel model has been 
proposed. In this model the human fetal bowel is 
transplanted into a subcutaneous tullel on the back of 
thymic nude mice, which vascularizes within 4 weeks, 
matures and becomes capable of developing of 
mucosal immune system from the host [24].   
 
Figure 3. Cross-section of the OROS-CT colon 
targeted drug delivery system. 
 
Drug delivery index (DDI)  
DDI is calculated pharmacokinetic parameters; 
following single is multiple doses of oral colonic 
prodrugs. DDI is the relative ratio of RCE (Relative 
colonic tissue exposure to the drug) to RSC (Relative 
amount of drug in blood i.e. that is relative systemic 
exposal to the drug). High drug DDI value indicates 
better colon drug delivery. 
 
Clinical evaluation of colon-specific drug delivery 
system  
Absorption of drugs from the colon is monitored by 
colonoscopy and intubation. Currently gama 
scintigraphy and high frequency capsules are the most 
preferred techniques employed to evaluate colon drug 
delivery systems [30]. 
 
Conclusion  
The colonic region of the GIT has become an 
increasingly important site for drug delivery and 
absorption. CDDS offers considerable therapeutic 
benefits to patients in terms of both local and systemic 
treatment. For colon targeted drug delivery four 
primary approaches were proposed for CDDS: 
prodrugs, pH and time dependent systems and 
micobletriggered drug delivery system. Of these first 
three approaches is not ideal for CDDS. Novel 
Tiwari et al. International Journal of Drug Delivery 2 (2010) 01-11 
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approaches developed for CDDS are more specific. 
Colon specificity is more likely to be achieved with 
systems that utilize natural materials that are degraded 
by colonic bacterial enzymes. For in vitro evaluation of 
a colon-specific drug delivery system, it seems that 
more than one testing method is necessary to 
characterize drug release and justify system design 
rationale. Considering the sophistication of colon-
specific drug delivery systems and the uncertainty of 
current dissolution methods in establishing possible in 
vitro/in vivo correlation, challenges remain for 
pharmaceutical scientists to develop and validate a 
dissolution method that incorporates the physiological 
features of the colon and yet can be used routinely in 
an industry setting for the evaluation of CDDS.  
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